Trial Profile

A Phase II Study of Acalabrutinib in Combination With R-CHOP Chemotherapy in Previously Untreated Mantle Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms The Rectangle Trial

Most Recent Events

18 Feb 2025 Planned number of patients changed from 54 to 105.
18 Feb 2025 Planned End Date changed from 30 Nov 2028 to 30 Apr 2032.
18 Feb 2025 Status changed to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com